Abbott Laboratories (ABT)
Debt-to-capital ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 47,664,000 | 39,796,000 | 39,318,000 | 38,810,000 | 38,603,000 | 37,481,000 | 37,174,000 | 74,219,000 | 36,686,000 | 35,675,000 | 36,490,000 | 35,399,000 | 35,802,000 | 34,422,000 | 33,800,000 | 33,562,000 | 32,784,000 | 31,386,000 | 30,578,000 | 30,218,000 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $47,664,000K)
= 0.00
The debt-to-capital ratio for Abbott Laboratories has consistently remained at 0.00 for each reporting period from March 31, 2020, to December 31, 2024. This indicates that the company has not used any debt to finance its operations or investments relative to its capital structure during these periods. A debt-to-capital ratio of 0.00 suggests that the company has been mainly reliant on equity financing, which can be seen as a positive sign of financial stability and lower financial risk. Abbott Laboratories' consistent zero debt-to-capital ratio reflects a financially healthy position with a lower reliance on borrowing, which may be favorable for its long-term growth and sustainability.
Peer comparison
Dec 31, 2024